Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALACE: Adaptive Cemiplimab Strategy in Advanced NSCLC
NCT06917573Phase 2Recruiting
- Sponsor
- Fundación GECP
- Start
- Jul 2025
- Primary completion
- Dec 2031
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Primary endpoint: Overall Survival at 24 months. Started Jul 2025; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06917573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917573.